Vytrus Biotech Increases Sales by 31% and Achieves an EBITDA of €1.5 Million

Vytrus Biotech, a company specializing in active ingredients derived from plant stem cells for the cosmetics industry, closed 2022 with €3.7 million in sales, a record for the firm, while gross operating profit (Ebitda) was €1.5 million, 30% more than in the same period of the previous year, as reported to the market.

Read more about Vytrus Biotech and find other important financial news with the Born2Invest mobile app.

Thanks to the good sales performance, the BME Growth listed company posted a net profit of €605,000, 34% more than in the same period of the previous year

Vytrus Biotech has continued to drive its international expansion in the 5 continents and sales outside Spain now exceed 66% in 33 countries.

Albert Jané, COO and co-founder of Vytrus, said that “growing again above 30% in sales and profits in a year as complex as 2022 is a sign of the strength and scalability of Vytrus Biotech’s business model”. For his part, Óscar Expósito, CSO and co-founder of Vytrus has highlighted that “in addition to the good business figures, 2022 has given us the award of a triple patent in Europe, USA, and Japan that reinforces the company’s commitment to lead technological innovation and set trends in the cosmetics sector”.

The executives of the biotech company have expressed their satisfaction with the good reception that the 2022 launches are having in the market. Specifically, Elaya Renova™ (an ingredient for hair care) has been awarded the innovation prizes at thein-cosmetics Latin America and in-cosmetics Asia 2022 fairs, while Quora Noni™ biomics (an active for microbiota and skin rejuvenation, for the first time in cosmetics) has been awarded the first position at the Cosmetorium 2022 Awards, a reference fair for the cosmetics industry in Spain.

The company’s innovation has also been widely recognized at 2022. On the one hand, Vytrus won the First BBVA Award for innovation in environmental sustainability. On the other hand, Vytrus was awarded in the Cinco Días awards for Business Innovation in its 2022 edition at an event held in Madrid.

In the last week of March, the company will participate as an exhibitor at in-cosmetics Global 2022 in Barcelona, the world’s leading cosmetics trade fair, where it will present its latest launch from plant stem cells Photobiome™, an ingredient that, for the first time in cosmetics, helps the skin’s microbiota (the most superficial bacterial layer) to photoprotect itself, while improving skin aging damage caused by solar radiation.

As a result of its innovation, Photobiome™ is a finalist in two industry benchmark competitions. On the one hand, the innovation awards of in-cosmetics Global 2023 (Best Ingredient Awards), the world’s leading trade fair for cosmetic ingredients, held this year in Barcelona. On the other hand, the product is also a finalist in the BSB Innovation Awards, a global benchmark award from Germany. For both competitions, the juries that evaluate the product are made up of the industry’s major customers, who assess the degree of innovation that the product brings to the cosmetics market.

Vytrus Biotech was the second most profitable company on the Spanish stock exchange in 2022

The company closed 2022 with a capitalization of more than €24 million, an increase of 98% since its debut on BME Growth, the SME stock market, in March. This positions it as the second most profitable company in 2022 in the entire Spanish market after the renewables company EIDF.

The majority stake in the company remains in the hands of its founding shareholders Albert Jané and Óscar Expósito, with 40% of the capital, followed by the Zamit Capital Fund with 7.9%, the Institut Català de Finances with 6.2% and the Perfumerias Julia Group with 5.4%.

This evolution of the share value reflects the good reception of Vytrus by the market and even more so within the current framework of uncertainty experienced by the global stock markets.

__

(Featured image by fotostrobi via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ESTRATEGIAS de INVERSION, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.